Head to head

5-Amino-1MQ vs MOTS-c

Metabolic

Two compounds that are more often stacked than compared — the side-by-side data, and what actually separates them.

Verdict

Usually stacked; if you must pick, route decides

5-Amino-1MQ and MOTS-c appear in each other's stacks in this dataset, so the most common real-world use is together rather than instead of. Nothing in the evidence separates them cleanly, so the practical difference is the one that decides it: MOTS-c means a vial and a needle, 5-Amino-1MQ does not.

What you are actually choosing between

Before anything else: the dataset lists 5-Amino-1MQ and MOTS-c in each other's stacks. They are run together more often than they are chosen between, so if you came here for a winner, the first honest answer is that this may not be an either/or.

Both are classed here as metabolic compounds, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is metabolic health and fat loss. On this site's goal weighting — an editorial priority score, not a measure of effect size — 5-Amino-1MQ rates 4/5 for metabolic health and MOTS-c rates 5/5.

The evidence

MOTS-c sits one step firmer: some human data, but it is small, old, or uncontrolled — the human data is observational, not interventional. 5-Amino-1MQ has animal and cell data only, and no controlled human dosing trials — dose figures are extrapolated from vendor and community practice. One tier is a real difference but not a decisive one; it should not on its own settle the choice.

How they differ in practice

5-Amino-1MQ is taken by mouth; MOTS-c is a subcutaneous injection. That is the difference most people actually feel: MOTS-c means reconstituting a vial and injecting; 5-Amino-1MQ does not require either. If needles are the deciding factor, this line settles it before any of the rest matters.

No half-life is published for either compound in this dataset. That absence is itself information: it means the pharmacokinetics have not been characterized well enough to quote, so both dosing schedules — once daily for 5-Amino-1MQ, twice a week for MOTS-c — are convention.

Committed time differs: 5-Amino-1MQ runs 12 weeks, MOTS-c runs 8 weeks.

Risk and difficulty

5-Amino-1MQ is rated intermediate here and MOTS-c advanced. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.

Source notes

What the evidence actually says

Verbatim, so you can check the verdict above against what it was built from.

5-Amino-1MQ

A small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor, not a peptide. Evidence is preclinical: it reduced fat mass in diet-induced obese mice without changing food intake, and there are cell and rodent data on muscle stem cells. There are no published controlled human trials, so every dose figure here is extrapolated from vendor and community practice rather than clinical data — treat the range as low confidence. It is taken orally in capsules: 50-150 mg daily, with 100 mg typical, which in the microgram units used throughout this dataset is 50,000-150,000 mcg (100 mg = 100,000 mcg). It is swallowed as capsules rather than reconstituted, so the reconstitution fields do not apply.

MOTS-c

A 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA gene. Mechanistically it is linked to AMPK activation and the folate / one-carbon pathway. The strong data are preclinical: injected MOTS-c improved insulin sensitivity, reduced diet-induced obesity and improved physical capacity in mice, including in aged animals. Human data is limited and mostly observational rather than interventional — circulating MOTS-c levels have been measured in relation to exercise, age, insulin resistance and a longevity-associated mitochondrial variant, but there is no established human dosing trial and no approved product. The figures here are compounding-pharmacy and community convention scaled off the 10 mg vial that is the usual market size, not trial-derived doses. The starting point is 2.5 mg twice a week; 5 mg once a week is the same weekly total and is run the same way. Vendor guides also describe a daily 0.5-1 mg microdose pattern, which reaches comparable weekly exposure by a different route. Human half-life has not been characterized, so it is left null rather than estimated.

Side by side

The numbers

5-Amino-1MQ compared with MOTS-c
Attribute	5-Amino-1MQ	MOTS-c
Class	Metabolic	Metabolic
Routes	Oral	Subcutaneous
Dose range	50 mg–150 mg (typical 100 mg)	2.5 mg–5 mg (typical 2.5 mg)
Frequency	Once daily	Twice a week
Half-life	Not characterized	Not characterized
Cycle length	12 weeks	8 weeks
Experience	Intermediate	Advanced
Evidence	Animal / cell data only	Limited human data
Contraindications	Pregnant / nursing Under 18	Pregnant / nursing Under 18
Side effects	Insomnia or restlessness if taken late in the day Mild nausea or stomach upset Headache Jitteriness in sensitive users	Injection site redness or soreness Fatigue or flushing after a dose Headache Longer-term safety in humans is simply unknown

Turn a typical dose into a mark on the syringe: MOTS-c

Goals

Where they overlap, and where they do not

Goal	5-Amino-1MQ	MOTS-c
metabolic health	5-Amino-1MQ: 4/5	MOTS-c: 5/5
fat loss	5-Amino-1MQ: 4/5	MOTS-c: 4/5
longevity	5-Amino-1MQ: 2/5	MOTS-c: 4/5
muscle growth	5-Amino-1MQ: 2/5	MOTS-c: 2/5
recovery and sleepone only	5-Amino-1MQ: —	MOTS-c: 2/5

They overlap on 4 goals and diverge on 1. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.

Go deeper

Monograph5-Amino-1MQMechanism, protocol, storage, sources.MonographMOTS-cMechanism, protocol, storage, sources.ToolReconstitution calculatorTurn either dose above into a mark on the syringe.

Other comparisons with these two

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.